HITIQ Valuation

Is HIQ undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of HIQ when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate HIQ's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate HIQ's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for HIQ?

Key metric: As HIQ is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for HIQ. This is calculated by dividing HIQ's market cap by their current revenue.
What is HIQ's PS Ratio?
PS Ratio	2.8x
Sales	AU$4.75m
Market Cap	AU$13.09m

HIQ key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	3.3x
Enterprise Value/EBITDA	-5.5x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does HIQ's PS Ratio compare to its peers?

The above table shows the PS ratio for HIQ vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	8.9x
SHG Singular Health Group	24.3x	n/a	AU$23.8m
ADR Adherium	8.9x	86.8%	AU$7.5m
IME ImExHS	0.7x	20.5%	AU$18.2m
VFX Visionflex Group	1.7x	n/a	AU$11.7m
HIQ HITIQ	2.8x	n/a	AU$13.1m

Price-To-Sales vs Peers: HIQ is good value based on its Price-To-Sales Ratio (2.8x) compared to the peer average (8.9x).

Price to Sales Ratio vs Industry

How does HIQ's PS Ratio compare vs other companies in the AU Healthcare Services Industry?

7 Companies	Price / Sales	Estimated Growth	Market Cap
MDR MedAdvisor	1.3x	13.4%	US$107.73m
DOC Doctor Care Anywhere Group	0.3x	6.3%	US$16.48m
IME ImExHS	0.7x	20.5%	US$11.89m
VFX Visionflex Group	1.7x	n/a	US$7.60m

7 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: HIQ is good value based on its Price-To-Sales Ratio (2.8x) compared to the Global Healthcare Services industry average (2.9x).

Price to Sales Ratio vs Fair Ratio

What is HIQ's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

HIQ PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	2.8x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate HIQ's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Doctor Care Anywhere Group

AU$25.3m

Provides digital healthcare and development services in the United Kingdom, Australia, and the Republic of Ireland.

DOC

AU$0.07

4.5%

45.8%

CardieX

AU$32.4m

Engages in the design, manufacture, and marketing of medical devices used in cardiovascular health management in the Americas, Europe, and the Asia Pacific.

CDX

AU$0.11

-24.1%

n/a

Cogstate

AU$170.7m

A neuroscience technology company, engages in the creation, validation, and commercialization of digital brain health assessments used in both academic and industry sponsored research.

CGS

AU$0.96

-2.5%

-36.9%